Javier Munoz, MD MS MBA
Dr. Munoz specializes in treating lymphomas and he is the Director of the Lymphoma Program at Mayo Clinic in Arizona. He is certified in Hematology and Medical Oncology. Dr. Munoz studied medicine in the “Universidad Peruana Cayetano Heredia” in Lima, Peru. Subsequently, he completed his residency and fellowship in Hematology-Oncology at Henry Ford Hospital in Michigan. Dr. Munoz also completed a Master of Science in patient-based research and an Investigational Cancer Therapeutics fellowship at the University of Texas MD Anderson Cancer Center in Houston before relocating to Arizona. Dr. Munoz also obtained an executive MBA in healthcare leadership and management for physicians from the University of Texas. Dr. Munoz was also the Director of Cancer Immunotherapy at Banner MD Anderson Cancer Center. He has been principal investigator in multiple cutting-edge lymphoma trials including immunotherapy and CAR T-cells. Within Mayo Clinic, Dr. Munoz is the Chair of the Feasibility Committee at a 3-site enterprise level and the Director of the Cancer Center Clinical Trials Office in Arizona. Dr. Munoz has published in internationally renowned journals including the New England Journal of Medicine, Nature Reviews, Blood, and JAMA. Dr. Munoz's personal goal is the development of non-chemotherapy agents, via novel clinical trials, to serve patients suffering with cancer.
Financial relationships
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Pharmacyclics/Abbvie, Bayer, Gilead/Kite, Beigene, Pfizer, Janssen, Celgene/BMS, Kyowa, Alexion, Fosunkite, Seattle Genetics, Karyopharm, Aurobindo, Verastem, Genmab, Genzyme, Genentech/Roche, ADC Therapeutics, Epizyme, Beigene, Novartis, Morphosys/IncyteTopic:ConsultingDate added:06/11/2024Date updated:06/11/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:MEI, TG Therapeutics, AstraZeneca, Eli LillyTopic:ConsultingDate added:06/11/2024Date updated:06/11/2024
-
Type of financial relationship:Financial SupportIneligible company:Bayer, Gilead/Kite, Celgene, Merck, Portola, Incyte, Genentech, Pharmacyclics, Seattle Genetics, Janssen, Millennium, Novartis, BeigeneTopic:Research fundingDate added:06/11/2024Date updated:06/11/2024
-
Type of financial relationship:OtherIneligible company:Targeted Oncology, OncView, Curio, and Physicians' Education ResourceTopic:HonorariaDate added:06/11/2024Date updated:06/11/2024